Melanonychia due to hydroxyurea therapy

V. Brazzelli, E. Bellani, T. Barbagallo, F. Prestinari, E. Roveda, V. Trevisan, C. Vassallo, S. Merante, G. Borroni

Research output: Contribution to journalArticle

Abstract

Hydroxyurea (HU) is a cytostatic agent which is widely used in the treatment of myeloproliferative disorders, in particular chronic myeloid leukemia. HU inhibits DNA synthesis through its action on ribonucleoside diphosphate-reductase, which catalyses the reduction of ribonucleotides. Its antitumor effect mainly consists of a decrease in white blood cell count, an increase in hemoglobin to normal values, a decrease of thrombocytosis and a reduction of splenomegaly. Long-term HU therapy causes hematologic side effects, including marrow suppression and megaloblastosis. Cutaneous adverse reactions are frequently described, and consist mainly of atrophy of the skin, leg ulcers, erythema of the face and hands, alopecia, hyperpigmentation of the skin and nail abnormalities. A 77-year-old woman with chronic myeloid leukemia was treated with oral HU (2 g/day) for 15 months. She complained of an ulcer of the left malleolar area, but the physical examination was also remarkable for diffuse and longitudinal nail hyperpigmentation of all the nails of both hands and feet. A diagnosis of HU-induced ulcer and melanonychia was made and HU was discontinued. The patient started a therapy with oral imatinib mesylate (400 mg/day) and oral pentoxifylline (400 mg/day). Two months later, the leg ulcer resolved and the hyperpigmented bands on the fingernails were lighter.

Original languageEnglish
Pages (from-to)723-726
Number of pages4
JournalGiornale Italiano di Dermatologia e Venereologia
Volume140
Issue number6
Publication statusPublished - 2005

Fingerprint

Hydroxyurea
Nails
Hyperpigmentation
Leg Ulcer
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Ulcer
Ribonucleoside Diphosphate Reductase
Malformed Nails
Therapeutics
Hand
Skin Abnormalities
Skin Ulcer
Ribonucleotides
Thrombocytosis
Pentoxifylline
Myeloproliferative Disorders
Splenomegaly
Alopecia
Cytostatic Agents
Erythema

Keywords

  • Chronic myeloid leukaemia
  • Hydroxyurea
  • Melanonychia

ASJC Scopus subject areas

  • Dermatology

Cite this

Brazzelli, V., Bellani, E., Barbagallo, T., Prestinari, F., Roveda, E., Trevisan, V., ... Borroni, G. (2005). Melanonychia due to hydroxyurea therapy. Giornale Italiano di Dermatologia e Venereologia, 140(6), 723-726.

Melanonychia due to hydroxyurea therapy. / Brazzelli, V.; Bellani, E.; Barbagallo, T.; Prestinari, F.; Roveda, E.; Trevisan, V.; Vassallo, C.; Merante, S.; Borroni, G.

In: Giornale Italiano di Dermatologia e Venereologia, Vol. 140, No. 6, 2005, p. 723-726.

Research output: Contribution to journalArticle

Brazzelli, V, Bellani, E, Barbagallo, T, Prestinari, F, Roveda, E, Trevisan, V, Vassallo, C, Merante, S & Borroni, G 2005, 'Melanonychia due to hydroxyurea therapy', Giornale Italiano di Dermatologia e Venereologia, vol. 140, no. 6, pp. 723-726.
Brazzelli V, Bellani E, Barbagallo T, Prestinari F, Roveda E, Trevisan V et al. Melanonychia due to hydroxyurea therapy. Giornale Italiano di Dermatologia e Venereologia. 2005;140(6):723-726.
Brazzelli, V. ; Bellani, E. ; Barbagallo, T. ; Prestinari, F. ; Roveda, E. ; Trevisan, V. ; Vassallo, C. ; Merante, S. ; Borroni, G. / Melanonychia due to hydroxyurea therapy. In: Giornale Italiano di Dermatologia e Venereologia. 2005 ; Vol. 140, No. 6. pp. 723-726.
@article{afefeb1b888840ebae7804560b0c2fb6,
title = "Melanonychia due to hydroxyurea therapy",
abstract = "Hydroxyurea (HU) is a cytostatic agent which is widely used in the treatment of myeloproliferative disorders, in particular chronic myeloid leukemia. HU inhibits DNA synthesis through its action on ribonucleoside diphosphate-reductase, which catalyses the reduction of ribonucleotides. Its antitumor effect mainly consists of a decrease in white blood cell count, an increase in hemoglobin to normal values, a decrease of thrombocytosis and a reduction of splenomegaly. Long-term HU therapy causes hematologic side effects, including marrow suppression and megaloblastosis. Cutaneous adverse reactions are frequently described, and consist mainly of atrophy of the skin, leg ulcers, erythema of the face and hands, alopecia, hyperpigmentation of the skin and nail abnormalities. A 77-year-old woman with chronic myeloid leukemia was treated with oral HU (2 g/day) for 15 months. She complained of an ulcer of the left malleolar area, but the physical examination was also remarkable for diffuse and longitudinal nail hyperpigmentation of all the nails of both hands and feet. A diagnosis of HU-induced ulcer and melanonychia was made and HU was discontinued. The patient started a therapy with oral imatinib mesylate (400 mg/day) and oral pentoxifylline (400 mg/day). Two months later, the leg ulcer resolved and the hyperpigmented bands on the fingernails were lighter.",
keywords = "Chronic myeloid leukaemia, Hydroxyurea, Melanonychia",
author = "V. Brazzelli and E. Bellani and T. Barbagallo and F. Prestinari and E. Roveda and V. Trevisan and C. Vassallo and S. Merante and G. Borroni",
year = "2005",
language = "English",
volume = "140",
pages = "723--726",
journal = "Minerva dermatologica",
issn = "0392-0488",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "6",

}

TY - JOUR

T1 - Melanonychia due to hydroxyurea therapy

AU - Brazzelli, V.

AU - Bellani, E.

AU - Barbagallo, T.

AU - Prestinari, F.

AU - Roveda, E.

AU - Trevisan, V.

AU - Vassallo, C.

AU - Merante, S.

AU - Borroni, G.

PY - 2005

Y1 - 2005

N2 - Hydroxyurea (HU) is a cytostatic agent which is widely used in the treatment of myeloproliferative disorders, in particular chronic myeloid leukemia. HU inhibits DNA synthesis through its action on ribonucleoside diphosphate-reductase, which catalyses the reduction of ribonucleotides. Its antitumor effect mainly consists of a decrease in white blood cell count, an increase in hemoglobin to normal values, a decrease of thrombocytosis and a reduction of splenomegaly. Long-term HU therapy causes hematologic side effects, including marrow suppression and megaloblastosis. Cutaneous adverse reactions are frequently described, and consist mainly of atrophy of the skin, leg ulcers, erythema of the face and hands, alopecia, hyperpigmentation of the skin and nail abnormalities. A 77-year-old woman with chronic myeloid leukemia was treated with oral HU (2 g/day) for 15 months. She complained of an ulcer of the left malleolar area, but the physical examination was also remarkable for diffuse and longitudinal nail hyperpigmentation of all the nails of both hands and feet. A diagnosis of HU-induced ulcer and melanonychia was made and HU was discontinued. The patient started a therapy with oral imatinib mesylate (400 mg/day) and oral pentoxifylline (400 mg/day). Two months later, the leg ulcer resolved and the hyperpigmented bands on the fingernails were lighter.

AB - Hydroxyurea (HU) is a cytostatic agent which is widely used in the treatment of myeloproliferative disorders, in particular chronic myeloid leukemia. HU inhibits DNA synthesis through its action on ribonucleoside diphosphate-reductase, which catalyses the reduction of ribonucleotides. Its antitumor effect mainly consists of a decrease in white blood cell count, an increase in hemoglobin to normal values, a decrease of thrombocytosis and a reduction of splenomegaly. Long-term HU therapy causes hematologic side effects, including marrow suppression and megaloblastosis. Cutaneous adverse reactions are frequently described, and consist mainly of atrophy of the skin, leg ulcers, erythema of the face and hands, alopecia, hyperpigmentation of the skin and nail abnormalities. A 77-year-old woman with chronic myeloid leukemia was treated with oral HU (2 g/day) for 15 months. She complained of an ulcer of the left malleolar area, but the physical examination was also remarkable for diffuse and longitudinal nail hyperpigmentation of all the nails of both hands and feet. A diagnosis of HU-induced ulcer and melanonychia was made and HU was discontinued. The patient started a therapy with oral imatinib mesylate (400 mg/day) and oral pentoxifylline (400 mg/day). Two months later, the leg ulcer resolved and the hyperpigmented bands on the fingernails were lighter.

KW - Chronic myeloid leukaemia

KW - Hydroxyurea

KW - Melanonychia

UR - http://www.scopus.com/inward/record.url?scp=31544447432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31544447432&partnerID=8YFLogxK

M3 - Article

VL - 140

SP - 723

EP - 726

JO - Minerva dermatologica

JF - Minerva dermatologica

SN - 0392-0488

IS - 6

ER -